[go: up one dir, main page]

US20130123294A1 - Formulations containing nalbuphine and uses thereof - Google Patents

Formulations containing nalbuphine and uses thereof Download PDF

Info

Publication number
US20130123294A1
US20130123294A1 US13/810,358 US201113810358A US2013123294A1 US 20130123294 A1 US20130123294 A1 US 20130123294A1 US 201113810358 A US201113810358 A US 201113810358A US 2013123294 A1 US2013123294 A1 US 2013123294A1
Authority
US
United States
Prior art keywords
pharmaceutical formulation
nalbuphine
formulation according
weight
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/810,358
Inventor
Christophe Lebon
Pascal Suplie
David Olivier Paul
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Debregeas Et Associes Pharma SAS
Original Assignee
Debregeas Et Associes Pharma SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43426302&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20130123294(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Debregeas Et Associes Pharma SAS filed Critical Debregeas Et Associes Pharma SAS
Assigned to DEBREGEAS ET ASSOCIES PHARMA reassignment DEBREGEAS ET ASSOCIES PHARMA ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: LEBON, CHRISTOPHE, PAUL, DAVID OLIVIER, SUPLIE, PASCAL
Publication of US20130123294A1 publication Critical patent/US20130123294A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core

Definitions

  • the subject-matter of the present invention is a pharmaceutical formulation containing nalbuphine and the use thereof for the treatment of pain.
  • Morphine derivatives have been widely used in the past to treat pain and their use has been substantially increased over the last ten years.
  • Nalbuphine is a semi-synthetic opiate derivative of receptor ⁇ -agonist and receptor ⁇ -antagonist type, belonging to the phenanthrene series. This molecule is classified by WHO under Schedule IIA. Its analgesic activity is equivalent to that of morphine and ten times greater than the activity of pentazocine.
  • nalbuphine is effectively an ideal analgesic: quick-acting, intense action, scarce inhibitor effect on the cardiovascular system and respiratory system, and no addictogenic effect.
  • nalbuphine is well absorbed via intravenous route (IV)
  • absorption via oral route is low and variable owing to strong first-pass metabolism in the liver. Therefore the forms of nalbuphine currently marketed are intended for parental, intramuscular or rectal route with the shortcomings and adverse effects associated with these routes of administration.
  • U.S. Pat. No. 6,680,067 concerns a controlled release GR pharmaceutical composition, in the form of an oily suspension, comprising an analgesic compound which is nalbuphine in base or salt form, in a mixture with oil for injection.
  • This composition is characterized in that it comprises micro-particles in the oil suspension, the particle size being less than 100 ⁇ m, obtained using an ultra high energy mixer allowing particles smaller than 100 microns in size to be obtained.
  • the Russian patent RU 02/254852 describes a solution of nalbuphine hydrochloride for injection.
  • compositions comprising nalbuphine or a salt thereof and a sustained release delivery system, said system comprising at least one hydrophilic compound, at least one cross-linking agent and at least one pharmaceutical diluent, or at least one hydrophilic compound, at least one cross-linking agent, at least one pharmaceutical diluent and at least one cationic cross-linking agent different from the 1st cross-linking agent or at least one hydrophilic compound, at least one cationic cross-linking agent and at least one pharmaceutical diluent.
  • international application WO 2005/127683 concerns essentially sustained release formulations of nalbuphine or a pharmaceutically acceptable salt thereof, intended for administration via oral route.
  • One of the objects of the invention presented herein is to provide clinicians with an oral form of nabulphine having swift action close to that of the IV form and that is sufficiently strong.
  • nalbuphine Another difficulty with the use of an oral form of nalbuphine lies in the particularly unpleasant intense taste of the active ingredient, which prevents direct use thereof in a solution. This assumes the need to mask the taste with usual galenic artefacts (flavouring or coating) which are detrimental to the immediate release of the active ingredient.
  • the objective of the present invention is to provide a novel, solid, oral pharmaceutical formulation comprising nalbuphine which allows rapid solubilization and bioavailability that is equivalent to those of a solute form of nalbuphine.
  • the present invention therefore concerns an immediate release, oral pharmaceutical formulation
  • hydrophilic any substance soluble or dispersible in water or in a polar solvent.
  • the pharmaceutical formulation only contains nalbuphine or one of its pharmaceutically acceptable salts as an active ingredient, preferably nalbuphine hydrochloride.
  • an oral, pharmaceutical formulation having immediate release comprising nalbuphine and at least one hydrophilic granulation carrier, one hydrophilic binder and one lubricant, allows good solubility to be obtained and hence bioavailability that is equivalent to that of a solution of nalbuphine for injection, administered orally.
  • the formulation of the invention therefore has efficacy in the treatment of pain that is equivalent to that of a formulation for injection and allows the immediate release of the active ingredient for swift treatment of pain.
  • the present invention therefore describes an oral, immediate release formulation of nalbuphine allowing in vivo results to be obtained that are comparable with those of a nalbuphine formulation for injection in a solution that is administered orally.
  • the expression pharmaceutical formulation with immediate release comprises all pharmaceutical formulations whose rate of release and absorption is not modified, in particular without any sustained release effect through any galenic manipulation.
  • immediate release is achieved through the use of at least one hydrophilic granulation carrier, one hydrophilic binder and one lubricant, pharmaceutically acceptable, which do not substantially extend the release or absorption of the formulation.
  • immediate-release excludes the formulations adapted for so-called sustained , extended or controlled release .
  • one immediate release form is a form in which the quantity of released substance is at least 75% in forty-five minutes ( Guidance for industry, dissolution testing of immediate release solid dosage forms 1997, FDA, CDER )
  • the formulation of the invention does not contain any cross-linking agent capable, in the presence of a hydrophilic compound, of forming a matrix which can be used for delayed release of the active ingredient.
  • cross-linking agent is meant homopolysaccharides for example, including guar gums, locust bean gums or cationic cross-linking agents.
  • One formulation can be characterized by its release kinetics in vitro.
  • an immediate release formulation according to the invention has in vitro release kinetics equal to or greater than 80% in 45 minutes.
  • nalbuphine or a salt thereof according to the invention includes nalbuphine, nabulphine hydrochloride/HCl, the esters of nalbuphine and their pharmaceutically acceptable salts, their complexes and derivatives.
  • the nalbuphine of the invention is in hydrochloride form.
  • pharmaceutically acceptable relates to molecules and formulations which do not induce any adverse, allergic or undesired reactions when administered to a mammal, human in particular.
  • the formulation of the invention comprises an hydrophilic granulation carrier, an hydrophilic binder and a lubricant.
  • the hydrophilic granulation carrier, the hydrophilic binder and the lubricant are chosen so as to allow highly rapid solubilization of the active ingredient, permitting swift treatment of pain.
  • the hydrophilic granulation carrier, the hydrophilic binder and the lubricant are selected so as not to modify the release of the active ingredient according to the changes in pH, which allows taking of the formulations according to the invention, independent of food intakes which may cause change in the gastric pH.
  • formulations of the invention effectively lead to near flash release of the active ingredient.
  • the expression granulation carrier comprises all the compounds allowing granulation of the pharmaceutical formulation according to the invention.
  • granulation is meant all the processes allowing particles of crystallized or amorphous powder to be converted to solid aggregates of greater or less resistance and greater or lesser porosity.
  • the hydrophilic granulation carrier is chosen from the group comprising polyols, for example mannitol, sorbitol, maltitol or xylitol, lactose, dicalcium phosphate, a carbonate e.g. calcium, potassium, magnesium or sodium carbonate, a gluconate, a silica derivative e.g. a silicate such as magnesium aluminium silicate (Neusilin® UFL2), sugar crystals, starch derivatives, saccharose, polyvinyl pyrrolidone (PVP) or a derivative thereof, a derivative of cellulose e.g. methylcellulose, hydroxypropyl methylcellulose or carboxy-methylcellulose, polyethylene glycol or one of its derivatives alone or in a mixture.
  • polyols for example mannitol, sorbitol, maltitol or xylitol, lactose, dicalcium phosphate, a carbonate e.g. calcium, potassium,
  • the hydrophilic granulation carrier of the invention is chosen from among mannitol, polyvinyl pyrrolidone or a derivative thereof, a polyol, lactose, a cellulose derivative e.g. methylcellulose, hydroxypropyl methylcellulose or carboxymethylcellulose, polyethylene glycol or a derivative thereof and a silica derivative.
  • the granulation carrier is mannitol.
  • At least one granulation carrier indicates that the pharmaceutical formulation of the invention may comprise one, two, three or more different granulation carriers.
  • the formulation of the invention may also comprise at least one hydrophilic binder
  • the binder of the invention can be chosen from among gums e.g. gum arabic or tragacanth gum, gelatin, starches, maltodextrins, polyethylene glycol e.g. PEG 4000 or 6000, PVP or a derivative thereof, solutions of saccharose, glucose or sorbitol, a polyol, lactose, carbomers, a cellulose derivative e.g. methylcellulose, hydroxypropyl methylcellulose or carboxymethylcellulose.
  • the binder is chosen from the group comprising PVP or a derivative thereof, a polyol, lactose, a cellulose derivative e.g. methylcellulose, hydroxypropyl methylcellulose or carboxymethylcellulose, polyethylene glycol or a derivative thereof, gums e.g. gum arabic and tragacanth, and carbomers.
  • the binder of the invention is PVP.
  • At least one hydrophilic binder indicates that the pharmaceutical formulation of the invention may comprise one, two, three or more different binders.
  • the formulation also comprises at least one lubricant.
  • the lubricant according to the invention may be selected from silicon dioxide, magnesium stearate, colloidal anhydrous silica, sodium stearylfumarate or talcum.
  • At least one lubricant indicates that the pharmaceutical formulation according to the invention may comprise one, two, three or more different lubricants.
  • the lubricant(s) are selected so that they do not have any influence on the kinetics of the release of the active ingredient(s).
  • the formulation comprises three different lubricants.
  • the formulation of the invention may contain other compounds such as at least one excipient for example.
  • the excipient which may be used in the formulations of the invention is chosen from among flavouring agents or taste-masking agents, sweeteners, colouring agents and disintegration agents such as polyvinylpyrrolidone.
  • the flavouring and taste masking agents are particularly desirable in the formulations of the invention to remove or attenuate the unpleasant taste of nalbuphine.
  • flavouring agent any substance used in the pharmaceutical industry intended to be added to formulations to modify or mask the taste or smell thereof.
  • Sweeteners may also be used that are natural or synthetic products having a sweet taste.
  • pharmaceutically acceptable sweeteners are used such as sugar substitutes (polyol derivatives, natural derivatives: stevia, etc.) and intense sweeteners (aspartam, cyclamate, saccharin etc.).
  • the formulation of the invention may further contain at least one film-forming agent in particular to form a cohesive coating to increase the stability of the formula or to mask the taste.
  • the film-forming agent is chosen from among cellulose derivatives, HPMC, polyethylene glycol derivatives, polyvinyl pyrrolidone derivatives, waxes, acrylic derivatives (for example Eudragit® L, RL, S) and carbomers.
  • the film-forming agent is more particularly selected so as to mask the taste while not acting on the release kinetics of the active ingredient(s).
  • the film-forming agent is preferably hydrophilic.
  • the formulation according to the invention represents a particular combination of excipients with which an oral release form with a flash effect may be obtained.
  • This flash effect release allows very fast release of the active ingredient(s).
  • the amount of release substance is at least 95% within fifteen minutes.
  • the amount of released substance is at least 75% within forty-five minutes ( Guidance for industry, dissolution testing of immediate release solid dosage forms 1997, FDA, CDER ).
  • the formulation according to the invention further comprises:
  • the formulation according to the invention may be completed by excipients, for example by compression agent(s).
  • the pharmaceutical formulation of the invention comprises less than 30% by weight of nalbuphine, preferably 4 to 30% by weight of nalbuphine and further preferably 18 to 22% by weight of nalbuphine relative to the total weight of the formulation.
  • the pharmaceutical formulation according to the invention comprises at least 45% by weight of hydrophilic granulation carrier, preferably from 45 to 70% by weight, and still preferably from 55 to 65% by weight of hydrophilic granulation carrier relative to the total weight of the formulation.
  • the pharmaceutical formulation of the invention comprises less than 10% by weight of hydrophilic binder, preferably from 2 to 10% by weight and still preferably from 4 to 8% by weight of binder relative to the total weight of the formulation.
  • the pharmaceutical formulation of the invention comprises less than 10% by weight of lubricant, preferably from 0.9 to 7% by weight and still preferably from 2 to 3% by weight of lubricant relative to the total weight of the formulation.
  • the formulation particularly comprises:
  • the pharmaceutical formulation of the invention is intended for oral administration.
  • the pharmaceutical formulation of the invention is preferably in solid form.
  • the solid forms of the invention particularly comprise tablets, granules, pellets, micro-granules, hard capsules, soft capsules, sublingual tablets, lozenges, pills, powders, sugar-coated tablets.
  • the solid form of the invention is chosen from the group comprising tablets, granules, pellets, micro-granules, soft capsules and lozenges.
  • the forms of the formulation according to the invention intended to be swallowed directly by the user such as soft capsules or tablets are particularly preferred. This administration mode allows sufficiently fast ingestion of the formulation without the user suffering discomfort from the unpleasant taste of nalbuphine.
  • the techniques used to obtain the solid form of the formulation according to the invention may consist of any methods known to those skilled in the art to obtain formulations in solid for.
  • these methods may be chosen from among the techniques of wet and dry granulation, direct pressing, fluidized bed granulation, film-coating and spray drying.
  • the formulation of the invention preferably allows good nalbuphine bioavailability.
  • good bioavailability is meant that a sufficient proportion of nalbuphine contained in the formulation will effectively act in the body compared with the absorbed quantity and will provide the desired therapeutic effect.
  • the invention concerns the pharmaceutical formulation such as defined above for use thereof as medicinal product in the treatment of pain, preferably in the treatment of non-chronic pain.
  • immediate-release formulations according to the invention for said use is such that they allow swift treatment of pain, contrary to sustained release formulations.
  • the pain which can be treated with the pharmaceutical formulations of the invention may be due to any cause, for example pain generated by opioid addiction treatment, by cancer, by autoimmune diseases, by infections and by trauma, etc.
  • the pain treated with the formulation of the invention is generated by treatment of opioid addiction.
  • the invention concerns the pharmaceutical formulation as defined above for its use as a drug in the treatment of opioid addiction.
  • FIG. 1 illustrates the different dissolution profiles of nalbuphine versus pH.
  • FIG. 2 illustrates the dissolved nalbuphine percentage versus time for the formulation of Example 5, according to different operating conditions.
  • compositions and methods to prepare 9 types of formulations are described below:
  • nalbuphine purified water and povidone (helix agitator);
  • talc Erweka mixer and 8 L cubic vessel
  • nalbuphine talc
  • Tablettose® granulation carrier
  • the dissolution conditions are the following:
  • the disintegration time for these coated tablets is greater than 8 hours 30 mins.
  • the disintegration time under the same operating conditions for Example 5 is located between 5 and 8 minutes.
  • the increase in bioavailability of the formulations is estimated in relation to the dissolution of the pharmaceutical form.
  • An immediate release form is a form in which the quantity of released substance is at least 75% in forty-five minutes ( Guidance for industry, dissolution testing of immediate release solid dosage forms 1997, FDA, CDER ). The dissolution profiles of the different formulations are obtained by dissolution measurements.
  • dissolution equipment equipped with impellers is used.
  • the formulations are subjected to constant agitation at 50 rpm in a vessel containing 500 ml purified water and held at 37° C.
  • Samples are taken at predetermined times, for 1 hour and then HPLC analyzed with ultraviolet detection at a wavelength of 285 nm.
  • Tmax time after which the maximum quantity of formulation is dissolved
  • Cmax maximum quantity of dissolved formulation
  • AUC concentration/time, area under curve
  • Tmax based on mean values
  • Formulation Tmax (h) 30 mg solid oral form of Example 1 1.25 30 mg oral solution (for comparison) IV form 0.75 administered per os It is ascertained that Tmax is slightly time-shifted for the solid oral form according to the invention compared with the liquid solution of nalbuphine.
  • Example 2 A second phase I study, with a single arm, was conducted on the oral formulation of Example 2 (30 mg tablets).
  • Tmax time after which the maximum quantity of formulation is dissolved
  • Cmax maximum quantity of dissolved formulation
  • AUC area located under the concentration versus time curve

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Immediate release, oral, pharmaceutical formulation including nalbuphine or a pharmaceutically acceptable salt thereof, and at least one hydrophilic granulation carrier, one hydrophilic binder and one lubricant.

Description

  • The subject-matter of the present invention is a pharmaceutical formulation containing nalbuphine and the use thereof for the treatment of pain.
  • Pain is a very common disorder and is one of the symptoms that is most frequently given therapeutic treatment.
  • Millions of individuals suffer continually from recurrent pain without receiving treatment that is fully satisfactory in terms of improvement in symptoms.
  • Morphine derivatives have been widely used in the past to treat pain and their use has been substantially increased over the last ten years.
  • Nalbuphine is a semi-synthetic opiate derivative of receptor κ-agonist and receptor μ-antagonist type, belonging to the phenanthrene series. This molecule is classified by WHO under Schedule IIA. Its analgesic activity is equivalent to that of morphine and ten times greater than the activity of pentazocine.
  • It is also used for anaesthesia. Its other advantage lies in the lower incidence of respiratory depression and addiction compared with other opiate derivatives.
  • With the following properties nalbuphine is effectively an ideal analgesic: quick-acting, intense action, scarce inhibitor effect on the cardiovascular system and respiratory system, and no addictogenic effect.
  • However, while nalbuphine is well absorbed via intravenous route (IV), absorption via oral route is low and variable owing to strong first-pass metabolism in the liver. Therefore the forms of nalbuphine currently marketed are intended for parental, intramuscular or rectal route with the shortcomings and adverse effects associated with these routes of administration.
  • Various pharmaceutical compositions containing nalbuphine have been previously researched and described.
  • International application WO 82/03768 describes a nasal form consisting of a solution, a suspension or an ointment. No mention is made of an oral form.
  • International applications WO 98/0951 and WO 00/24386 describe transdermal patches of active ingredient and notably nalbuphine hydrochloride.
  • U.S. Pat. No. 6,680,067 concerns a controlled release GR pharmaceutical composition, in the form of an oily suspension, comprising an analgesic compound which is nalbuphine in base or salt form, in a mixture with oil for injection. This composition is characterized in that it comprises micro-particles in the oil suspension, the particle size being less than 100 μm, obtained using an ultra high energy mixer allowing particles smaller than 100 microns in size to be obtained.
  • The Russian patent RU 02/254852 describes a solution of nalbuphine hydrochloride for injection.
  • International application WO 2007/025005 concerns sustained release formulations of nalbuphine or of one of the pharmaceutically acceptable salts thereof, intended for administration via oral route; this application describes compositions comprising nalbuphine or a salt thereof and a sustained release delivery system, said system comprising at least one hydrophilic compound, at least one cross-linking agent and at least one pharmaceutical diluent, or at least one hydrophilic compound, at least one cross-linking agent, at least one pharmaceutical diluent and at least one cationic cross-linking agent different from the 1st cross-linking agent or at least one hydrophilic compound, at least one cationic cross-linking agent and at least one pharmaceutical diluent.
  • Similarly, international application WO 2005/127683 concerns essentially sustained release formulations of nalbuphine or a pharmaceutically acceptable salt thereof, intended for administration via oral route.
  • One of the objects of the invention presented herein is to provide clinicians with an oral form of nabulphine having swift action close to that of the IV form and that is sufficiently strong.
  • There effectively does not exist any immediate, oral formulation at the present time since it has been observed that the immediate formulations tested up until now showed low bioavailability due to the bolus effect which causes saturation of the liver enzyme system (cytochrome p 450), which accounts for the reason why intensive research is focusing rather more on developing a sustained release form.
  • Another difficulty with the use of an oral form of nalbuphine lies in the particularly unpleasant intense taste of the active ingredient, which prevents direct use thereof in a solution. This assumes the need to mask the taste with usual galenic artefacts (flavouring or coating) which are detrimental to the immediate release of the active ingredient.
  • Research has therefore turned more towards sustained release formulations.
  • The objective of the present invention is to provide a novel, solid, oral pharmaceutical formulation comprising nalbuphine which allows rapid solubilization and bioavailability that is equivalent to those of a solute form of nalbuphine.
  • The present invention therefore concerns an immediate release, oral pharmaceutical formulation comprising nalbuphine or a pharmaceutically acceptable salt thereof and at least one hydrophilic granulation carrier, one hydrophilic binder and one lubricant.
  • By
    Figure US20130123294A1-20130516-P00001
    hydrophilic
    Figure US20130123294A1-20130516-P00002
    is meant any substance soluble or dispersible in water or in a polar solvent.
  • In a preferred embodiment of the invention, the pharmaceutical formulation only contains nalbuphine or one of its pharmaceutically acceptable salts as an active ingredient, preferably nalbuphine hydrochloride.
  • The present invention follows from the unexpected finding by the inventors that an oral, pharmaceutical formulation having immediate release, comprising nalbuphine and at least one hydrophilic granulation carrier, one hydrophilic binder and one lubricant, allows good solubility to be obtained and hence bioavailability that is equivalent to that of a solution of nalbuphine for injection, administered orally. The formulation of the invention therefore has efficacy in the treatment of pain that is equivalent to that of a formulation for injection and allows the immediate release of the active ingredient for swift treatment of pain.
  • The present invention therefore describes an oral, immediate release formulation of nalbuphine allowing in vivo results to be obtained that are comparable with those of a nalbuphine formulation for injection in a solution that is administered orally.
  • The expression pharmaceutical formulation
    Figure US20130123294A1-20130516-P00001
    with immediate release
    Figure US20130123294A1-20130516-P00002
    comprises all pharmaceutical formulations whose rate of release and absorption is not modified, in particular without any sustained release effect through any galenic manipulation. In the present case, immediate release is achieved through the use of at least one hydrophilic granulation carrier, one hydrophilic binder and one lubricant, pharmaceutically acceptable, which do not substantially extend the release or absorption of the formulation. The expression
    Figure US20130123294A1-20130516-P00001
    immediate-release
    Figure US20130123294A1-20130516-P00002
    excludes the formulations adapted for so-called
    Figure US20130123294A1-20130516-P00001
    sustained
    Figure US20130123294A1-20130516-P00002
    ,
    Figure US20130123294A1-20130516-P00001
    extended
    Figure US20130123294A1-20130516-P00002
    or
    Figure US20130123294A1-20130516-P00001
    controlled release
    Figure US20130123294A1-20130516-P00002
    . Preferably, one immediate release form is a form in which the quantity of released substance is at least 75% in forty-five minutes (
    Figure US20130123294A1-20130516-P00001
    Guidance for industry, dissolution testing of immediate release solid dosage forms 1997, FDA, CDER
    Figure US20130123294A1-20130516-P00002
    )
  • Preferably, the formulation of the invention does not contain any cross-linking agent capable, in the presence of a hydrophilic compound, of forming a matrix which can be used for delayed release of the active ingredient. By cross-linking agent is meant homopolysaccharides for example, including guar gums, locust bean gums or cationic cross-linking agents.
  • One formulation can be characterized by its release kinetics in vitro. Preferably, an immediate release formulation according to the invention has in vitro release kinetics equal to or greater than 80% in 45 minutes.
  • The expression
    Figure US20130123294A1-20130516-P00001
    nalbuphine or a salt thereof
    Figure US20130123294A1-20130516-P00002
    according to the invention includes nalbuphine, nabulphine hydrochloride/HCl, the esters of nalbuphine and their pharmaceutically acceptable salts, their complexes and derivatives. Preferably, the nalbuphine of the invention is in hydrochloride form.
  • The term
    Figure US20130123294A1-20130516-P00001
    pharmaceutically acceptable
    Figure US20130123294A1-20130516-P00002
    relates to molecules and formulations which do not induce any adverse, allergic or undesired reactions when administered to a mammal, human in particular.
  • The formulation of the invention comprises an hydrophilic granulation carrier, an hydrophilic binder and a lubricant. Preferably the hydrophilic granulation carrier, the hydrophilic binder and the lubricant are chosen so as to allow highly rapid solubilization of the active ingredient, permitting swift treatment of pain. Preferentially the hydrophilic granulation carrier, the hydrophilic binder and the lubricant are selected so as not to modify the release of the active ingredient according to the changes in pH, which allows taking of the formulations according to the invention, independent of food intakes which may cause change in the gastric pH.
  • The formulations of the invention effectively lead to near
    Figure US20130123294A1-20130516-P00001
    flash
    Figure US20130123294A1-20130516-P00002
    release of the active ingredient.
  • The expression
    Figure US20130123294A1-20130516-P00001
    granulation carrier
    Figure US20130123294A1-20130516-P00002
    comprises all the compounds allowing granulation of the pharmaceutical formulation according to the invention.
  • By
    Figure US20130123294A1-20130516-P00001
    granulation
    Figure US20130123294A1-20130516-P00002
    , is meant all the processes allowing particles of crystallized or amorphous powder to be converted to solid aggregates of greater or less resistance and greater or lesser porosity.
  • Preferably, the hydrophilic granulation carrier is chosen from the group comprising polyols, for example mannitol, sorbitol, maltitol or xylitol, lactose, dicalcium phosphate, a carbonate e.g. calcium, potassium, magnesium or sodium carbonate, a gluconate, a silica derivative e.g. a silicate such as magnesium aluminium silicate (Neusilin® UFL2), sugar crystals, starch derivatives, saccharose, polyvinyl pyrrolidone (PVP) or a derivative thereof, a derivative of cellulose e.g. methylcellulose, hydroxypropyl methylcellulose or carboxy-methylcellulose, polyethylene glycol or one of its derivatives alone or in a mixture.
  • Further preferably, the hydrophilic granulation carrier of the invention is chosen from among mannitol, polyvinyl pyrrolidone or a derivative thereof, a polyol, lactose, a cellulose derivative e.g. methylcellulose, hydroxypropyl methylcellulose or carboxymethylcellulose, polyethylene glycol or a derivative thereof and a silica derivative.
  • In one preferred embodiment, the granulation carrier is mannitol.
  • The expression
    Figure US20130123294A1-20130516-P00001
    at least one granulation carrier
    Figure US20130123294A1-20130516-P00002
    indicates that the pharmaceutical formulation of the invention may comprise one, two, three or more different granulation carriers.
  • The formulation of the invention may also comprise at least one hydrophilic binder, The binder of the invention can be chosen from among gums e.g. gum arabic or tragacanth gum, gelatin, starches, maltodextrins, polyethylene glycol e.g. PEG 4000 or 6000, PVP or a derivative thereof, solutions of saccharose, glucose or sorbitol, a polyol, lactose, carbomers, a cellulose derivative e.g. methylcellulose, hydroxypropyl methylcellulose or carboxymethylcellulose.
  • Preferably, the binder is chosen from the group comprising PVP or a derivative thereof, a polyol, lactose, a cellulose derivative e.g. methylcellulose, hydroxypropyl methylcellulose or carboxymethylcellulose, polyethylene glycol or a derivative thereof, gums e.g. gum arabic and tragacanth, and carbomers.
  • Further preferably, the binder of the invention is PVP.
  • The expression
    Figure US20130123294A1-20130516-P00001
    at least one hydrophilic binder
    Figure US20130123294A1-20130516-P00002
    indicates that the pharmaceutical formulation of the invention may comprise one, two, three or more different binders.
  • The formulation also comprises at least one lubricant. The lubricant according to the invention may be selected from silicon dioxide, magnesium stearate, colloidal anhydrous silica, sodium stearylfumarate or talcum.
  • The expression
    Figure US20130123294A1-20130516-P00001
    at least one lubricant
    Figure US20130123294A1-20130516-P00002
    indicates that the pharmaceutical formulation according to the invention may comprise one, two, three or more different lubricants. The lubricant(s) are selected so that they do not have any influence on the kinetics of the release of the active ingredient(s).
  • In one preferred embodiment, the formulation comprises three different lubricants.
  • The formulation of the invention may contain other compounds such as at least one excipient for example. Preferably, the excipient which may be used in the formulations of the invention is chosen from among flavouring agents or taste-masking agents, sweeteners, colouring agents and disintegration agents such as polyvinylpyrrolidone. The flavouring and taste masking agents are particularly desirable in the formulations of the invention to remove or attenuate the unpleasant taste of nalbuphine.
  • By
    Figure US20130123294A1-20130516-P00001
    flavouring agent
    Figure US20130123294A1-20130516-P00002
    is meant any substance used in the pharmaceutical industry intended to be added to formulations to modify or mask the taste or smell thereof. Sweeteners may also be used that are natural or synthetic products having a sweet taste. Preferably, pharmaceutically acceptable sweeteners are used such as sugar substitutes (polyol derivatives, natural derivatives: stevia, etc.) and intense sweeteners (aspartam, cyclamate, saccharin etc.).
  • The formulation of the invention may further contain at least one film-forming agent in particular to form a cohesive coating to increase the stability of the formula or to mask the taste. Preferably, the film-forming agent is chosen from among cellulose derivatives, HPMC, polyethylene glycol derivatives, polyvinyl pyrrolidone derivatives, waxes, acrylic derivatives (for example Eudragit® L, RL, S) and carbomers. The film-forming agent is more particularly selected so as to mask the taste while not acting on the release kinetics of the active ingredient(s). The film-forming agent is preferably hydrophilic.
  • The formulation according to the invention represents a particular combination of excipients with which an oral release form with a
    Figure US20130123294A1-20130516-P00001
    flash effect
    Figure US20130123294A1-20130516-P00002
    may be obtained. This
    Figure US20130123294A1-20130516-P00001
    flash effect
    Figure US20130123294A1-20130516-P00002
    release allows very fast release of the active ingredient(s). Indeed, with the formulation according to the invention, the amount of release substance is at least 95% within fifteen minutes. For a conventional immediate release form, the amount of released substance is at least 75% within forty-five minutes (
    Figure US20130123294A1-20130516-P00001
    Guidance for industry, dissolution testing of immediate release solid dosage forms 1997, FDA, CDER
    Figure US20130123294A1-20130516-P00002
    ).
  • In one preferred embodiment, the formulation according to the invention further comprises:
      • at least one disintegrating agent;
      • at least one excipient.
  • The formulation according to the invention may be completed by excipients, for example by compression agent(s).
  • In some preferred embodiments, the pharmaceutical formulation of the invention comprises less than 30% by weight of nalbuphine, preferably 4 to 30% by weight of nalbuphine and further preferably 18 to 22% by weight of nalbuphine relative to the total weight of the formulation.
  • In some preferred embodiments, the pharmaceutical formulation according to the invention comprises at least 45% by weight of hydrophilic granulation carrier, preferably from 45 to 70% by weight, and still preferably from 55 to 65% by weight of hydrophilic granulation carrier relative to the total weight of the formulation.
  • In some preferred embodiments, the pharmaceutical formulation of the invention comprises less than 10% by weight of hydrophilic binder, preferably from 2 to 10% by weight and still preferably from 4 to 8% by weight of binder relative to the total weight of the formulation.
  • In some preferred embodiments, the pharmaceutical formulation of the invention comprises less than 10% by weight of lubricant, preferably from 0.9 to 7% by weight and still preferably from 2 to 3% by weight of lubricant relative to the total weight of the formulation.
  • In one other preferred embodiment of the invention, the formulation particularly comprises:
      • from 4 to 30% by weight of nalbuphine,
      • from 45 to 70% by weight of lactose,
      • from 2 to 10% by weight of PVP; and
      • from 0.9 to 7% by weight of at least one lubricant, completed with excipients.
  • The pharmaceutical formulation of the invention is intended for oral administration. The pharmaceutical formulation of the invention is preferably in solid form. The solid forms of the invention particularly comprise tablets, granules, pellets, micro-granules, hard capsules, soft capsules, sublingual tablets, lozenges, pills, powders, sugar-coated tablets. Preferably the solid form of the invention is chosen from the group comprising tablets, granules, pellets, micro-granules, soft capsules and lozenges. The forms of the formulation according to the invention intended to be swallowed directly by the user such as soft capsules or tablets are particularly preferred. This administration mode allows sufficiently fast ingestion of the formulation without the user suffering discomfort from the unpleasant taste of nalbuphine.
  • The techniques used to obtain the solid form of the formulation according to the invention may consist of any methods known to those skilled in the art to obtain formulations in solid for. In particular, these methods may be chosen from among the techniques of wet and dry granulation, direct pressing, fluidized bed granulation, film-coating and spray drying.
  • The formulation of the invention preferably allows good nalbuphine bioavailability. By
    Figure US20130123294A1-20130516-P00001
    good bioavailability
    Figure US20130123294A1-20130516-P00002
    , is meant that a sufficient proportion of nalbuphine contained in the formulation will effectively act in the body compared with the absorbed quantity and will provide the desired therapeutic effect.
  • In one particular embodiment, the invention concerns the pharmaceutical formulation such as defined above for use thereof as medicinal product in the treatment of pain, preferably in the treatment of non-chronic pain.
  • The advantage of immediate-release formulations according to the invention for said use is such that they allow swift treatment of pain, contrary to sustained release formulations.
  • The pain which can be treated with the pharmaceutical formulations of the invention may be due to any cause, for example pain generated by opioid addiction treatment, by cancer, by autoimmune diseases, by infections and by trauma, etc.
  • Preferably the pain treated with the formulation of the invention is generated by treatment of opioid addiction.
  • In one preferred embodiment, the invention concerns the pharmaceutical formulation as defined above for its use as a drug in the treatment of opioid addiction.
    • DESCRIPTION OF THE FIGURES
  • FIG. 1 illustrates the different dissolution profiles of nalbuphine versus pH.
  • FIG. 2 illustrates the dissolved nalbuphine percentage versus time for the formulation of Example 5, according to different operating conditions.
    •  EXAMPLES Preparation of the Pharmaceutical Formulations in Tablet Form
  • The compositions and methods to prepare 9 types of formulations (Example 1, Example 2, Example 3, Example 4, Example 5, Example 6, Example 7, Example 8, and Example 9) are described below:
    • Example 1 30 mg Tablets
  • Formula
    Raw materials Unit (mg) %
    Nalbuphine/HCl 30.00 4.69
    Povidone (PVP) 242.01 37.80
    Mannitol (granulation carrier) 349.49 54.58
    Crospovidone 12.81 2.00
    Anhydrous colloidal silica 0.64 0.10
    Sodium stearylfumarate 3.20 0.50
    Talc 2.14 0.33
    TOTAL 640.29 100.00
  • This formulation was obtained following the protocol below:
  • weighing of raw materials (scales);
  • mixing nalbuphine, purified water and povidone (helix agitator);
  • solubilizing and complexing the mixture (GPCG3 fluidized bed, Würster and peristaltic pump);
  • coating mannitol with the mixture and drying the coated mannitol to obtain granules;
  • screening the granules (mesh size 600 μm diameter, oscillating screen, mesh of 630, 500 and 400 μm);
  • lubricating the granules by adding talc (Erweka mixer and 8 L cubic vessel);
  • mixing and lubricating the granules with mannitol, povidone, crospovidone, anhydrous colloidal silica, sodium stearylfumarate (Erweka mixer and 8 L cubic vessel);
  • obtaining tablets from the mixture (SVIAC RP2080 rotary press, 13 mm dies).
    • Example 2 30 mg Tablets
  • Formula
    Raw materials Unit (mg) %
    Nalbuphine/HCl 30.00 18.65
    Talc 4.47 2.70
    Anhydrous colloidal silica 0.74 0.45
    Avicel PH 200 (granulation carrier) 23.17 14.00
    Tablettose 80 (granulation carrier) 79.44 48.00
    Povidone 7.45 4.50
    Magnesium stearate 0.74 0.45
    Sepifilm LP014 14.89 9.00
    Crospovidone 3.72 2.25
    96° Alcohol Surfin Pharma / /
    Purified water / /
    TOTAL 320.15 100.00
  • This formulation was obtained following the protocol below:
  • weighing the raw materials (scales);
  • mixing the nalbuphine, talc and Tablettose® and Avicel®;
  • obtaining a binder solution by mixing povidone and purified water;
  • spraying the binder solution on the first mixture to obtain a granulate;
  • drying the obtained granulate in an air fluidized bed;
  • lubrication by adding magnesium stearate and anhydrous colloidal silica; XL, homogenization and incorporation to the granulate
  • direct compression of the mixture;
  • Preparation of the film-coating suspension: Sepifilm® LP014 and alcohol;
  • Film coating and then drying.
    • Example 3 10 mg Tablets
  • Formula
    Raw materials Unit (mg) %
    Nalbuphine/HCl 10.00 11.86
    Avicel ® PH200 (microcrystalline cellulose) 15.54 18.43
    (granulation carrier)
    Talc 1.54 1.83
    Tablettose ® 80 (agglomerated α-lactose 44.94 53.28
    monohydrate) (granulation carrier)
    Magnesium stearate 0.39 0.46
    Aerosil ® 200 (silica) 0.39 0.46
    PVP K30 3.85 4.56
    Sepifilm LP014 (coating) 7.70 9.13
    TOTAL 84.70 100.00
  • This formulation was obtained following the protocol given below:
  • weighing the raw materials (scales);
  • homogenizing on a cubic mixer (8 L), 5 minutes at 150 rpm, (Nalbuphine, Avicel® PH200, talc, Aerosil® 200, Tablettose® 80 and PVP K30);
  • lubricating the mixture with magnesium stearate for 1 minute at 150 rpm;
  • compressing the mixture on Korsch equipment (G009, diameter 9);
  • preparing the coating solution with Sepifilm LP014 and purified water on a magnetic plate;
  • aqueous coating of the compressed mixture on LAF GPCG 1.
    • Example 3-1 50 mg Tablets
  • Formula
    Raw materials Unit (mg) %
    Nalbuphine/HCl 51.60 20.55
    Avicel ® ph 200 (microcrystalline 119.35 47.53
    cellulose) (granulation carrier)
    PVP CL 12.50 4.98
    Lactose 55.30 22.02
    Magnesium stearate 1.25 0.50
    Flavouring agent 10.01 3.98
    Sepifilm IR 777 1.08 0.44
    TOTAL 251.09 100.00
  • This formulation was obtained following the protocol given below:
  • weighing the raw materials (scales);
  • homogenizing on a cubic mixer (8 L), 5 minutes at 150 rpm (Nalbuphine, Avicel®, lactose, PVP CL and flavouring agent);
  • lubricating the mixture with magnesium stearate for 1 minute at 150 rpm;
  • compressing the mixture on Korsch (G009, diameter 9);
  • preparing the coating mixture with Sepifilm IR 777, purified water and flavouring agent on a magnetic plate;
  • aqueous coating of the compressed mixture on LAF GPCG 1.
    • Example 4 10 mg Pellets
  • Formula
    Raw materials Unit (mg) %
    Nalbuphine/HCl 10.00 1.99
    Taste masking agent 146.72 29.20
    PEG 400 139.71 27.80
    Sucralose (sweetener) 18.54 3.69
    Caramel flavouring 12.84 2.56
    Neusilin UFL2 (granulation carrier) 107.00 21.29
    Povidone K30 (PVP) 32.61 6.49
    Sepifilm LP014 32.60 6.49
    Talc 2.50 0.50
    TOTAL 502.52 100.00
  • This formulation was obtained following the protocol given below:
  • weighing the raw materials (scales);
  • dispersing PEG 400, nalbuphine, sucralose, taste masking agent, caramel flavouring in ethanol (agitator);
  • impregnating (mixer and peristaltic pump) Neusilin UFL2 with this mixture, calibration (oscillating rotor) and drying (fluidized bed dryer, top spraying);
  • adding PVP 30 and purified water and granulating the mixture obtained (fluidized bed dryer, top spraying vessel);
  • calibrating the pellets (oscillating rotor and 800 μm mesh);
  • adding Sepifilm LP104 and water to coat the particles and drying (fluidized bed granulator, Würster vessel);
  • lubricating the coated particles with talc (cubic mixer).
    • Example 5 30 mg Tablets
  • Formula
    Raw materials Unit (mg) %
    Nalbuphine 30.00 20.31
    PVP K30 9.83 6.65
    Polyplasdone XL 3.52 2.38
    Avicel ® PH200 1.19 1.76
    Tablettose ® 80 91.85 62.16
    Aerosil ® 200 0.14 0.10
    Magnesium stearate 0.71 0.48
    Talc 2.83 1.92
    Sepifilm LP014 7.11 4.81
    Purified water / /
    TOTAL 147.75 100.00
  • This formulation was obtained following the protocol below:
  • weighing the raw materials (scales);
  • mixing the nalbuphine, talc and Tablettose® (granulation carrier);
  • obtaining a binder solution by mixing purified water with PVP K30;
  • spraying the binder solution on the first mixture to obtain a granulate;
  • drying the obtained granulate in an air fluidized bed;
  • mixing Avicel®, Aerosil® and Polyplasdone
  • XL, homogenization and incorporation to the granulate;
  • lubrication by adding magnesium stearate and anhydrous colloidal silica;
  • direct compression of the mixture;
  • preparation of the film-coating suspension: Sepifilm® LP014 and purified water;
  • Film coating and then drying.
    • Example 6 Comparative Study of the Disintegration Time of the Tablets with Formulations Having Different Granulation Carrier
  • Replacement of Tablettose 80 with calcium glycerophosphate
  • Coated tablets
    Raw materials g mg % mg obtained
    Nalbuphine 63.978 30.865 20.659 30.947
    Talc 5.880 2.837 1.899 2.844
    calcium glycerophosphate 190.522 91.913 61.520 92.157
    25% PVP K30 20.398 9.840 6.586 9.867
    Polyplasdone XL 8.130 3.922 2.625 3.932
    Avicel ph 200 4.067 1.962 1.313 1.967
    Aerosil 200 0.332 0.160 0.107 0.160
    Mg stearate 1.634 0.788 0.528 0.790
    Sepifilm LP 014 14.750 7.116 4.763 7.135
    Purified water 132.72 — — —
    TOTAL 309.690 149.40 100.00 149.80
  • The amounts of raw materials are very close to those of the composition of Example 5. Only the granulation carrier was changed in this composition of coated tablets.
  • The tablets according to the composition above and tablets according to the composition of Example 5 are tested.
  • They are subject to constant stirring in a medium maintained at 37.0° C. (+/−0.5° C.) in a dissolution apparatus. Samples are taken, by means of a piston pump and a sample collector at 5, 10, 15, 30 and 60 minutes. These samples are then analyzed by HPLC.
  • The dissolution conditions are the following:
      • apparatus 1 USP<711> (apparatus with baskets)
      • speed of rotation: 50 rpm.
      • dissolution medium: HCl 0.1N
      • volume: 500 Ml.
      • Test sample: a 30 mg tablet.
  • The disintegration time for these coated tablets is greater than 8 hours 30 mins.
  • The disintegration time under the same operating conditions for Example 5 is located between 5 and 8 minutes.
    • Example 7 Study of Dissolution in Media with Different pH
  • The operating conditions are identical with those used for the previous comparative study.
  • During this study, several media with different pH were tested: HCl 0.1N, at pH 1.2, 4.5 and 6.8 (FIG. 1).
  • It is seen that the pH and the nature of the medium have practically no influence on the dissolution profile of the formulation.
    • Example 8 Solubility of the Formulations
  • The increase in bioavailability of the formulations is estimated in relation to the dissolution of the pharmaceutical form.
  • An immediate release form is a form in which the quantity of released substance is at least 75% in forty-five minutes (
    Figure US20130123294A1-20130516-P00001
    Guidance for industry, dissolution testing of immediate release solid dosage forms 1997, FDA, CDER
    Figure US20130123294A1-20130516-P00002
    ). The dissolution profiles of the different formulations are obtained by dissolution measurements.
  • For this purpose, dissolution equipment equipped with impellers is used. The formulations are subjected to constant agitation at 50 rpm in a vessel containing 500 ml purified water and held at 37° C.
  • Samples are taken at predetermined times, for 1 hour and then HPLC analyzed with ultraviolet detection at a wavelength of 285 nm.
    • Formulation of Example 1
  • Time (min)
    5 15 30 45
    % Nalbuphine 84 96 97 97
    dissolution
    • Formulation of Example 3
  • Time (min)
    5 15 30
    % Nalbuphine 84 93 96
    dissolution
    • Formulation of Example 4
  • Time (min)
    5 10 15
    % Nalbuphine 97 99 98
    dissolution

    As shown by the results of these experiments, the different formulations presented were specifically developed to obtain very fast dissolution times, conforming to the definition.
    • Example 9 Pharmacokinetic Study
  • An open Phase I trial, two arms, was conducted with the following formulations:
      • oral formulation of Example 1 (30 mg tablets)
      • intravenous form (IV) of nalbuphine administered orally
  • A trial was conducted comprising the administration of a single dose to 8 fasting, healthy male volunteers (4 volunteers per arm). Different parameters were measured: Tmax (time after which the maximum quantity of formulation is dissolved), Cmax (maximum quantity of dissolved formulation) and AUC (concentration/time, area under curve). The following results were obtained:
  • TABLE 1
    Tmax based on mean values
    Formulation Tmax (h)
    30 mg solid oral form of Example 1 1.25
    30 mg oral solution (for comparison) IV form 0.75
    administered per os

    It is ascertained that Tmax is slightly time-shifted for the solid oral form according to the invention compared with the liquid solution of nalbuphine.
  • TABLE 2
    Pharmacokinetic parameters, arithmetic mean value
    Cmax Tmax AUCt AUCinf
    Formulation (ng/mL) (h) (ng/mL * h) (ng/mL * h)
    30 mg solid oral form of 7.91 1.21 30.93 38.08
    Example 1
    30 mg oral solution (for 9.34 0.71 33.06 39.07
    comparison) IV form
    administered per os

    It is ascertained that, aside from the slight difference for Tmax, the pharmacokinetic parameters are comparable for the solid form of the invention and for the oral solution.
  • TABLE 3
    Relative Bioavailability (based on dose-normalized,
    arithmetic mean value)
    AUCinf
    Formulation Cmax ratio AUCt ratio ratio
    30 mg solid oral form of 0.85 0.94 0.97
    Example 1/30 mg oral solution
    (for comparison)
  • TABLE 4
    Pharmacokinetic parameters, geometric mean value
    Cmax AUCinf
    Formulation (ng/mL) AUCt (ng/mL * h) (ng/mL * h)
    30 mg solid oral form of 6.72 26.22 31.80
    Example 1
    30 mg oral solution (for 8.63 29.72 34.47
    comparison)
  • TABLE 5
    Relative bioavailability (based on dose-normalized geometric mean value)
    Formulation Cmax ratio AUCt ratio AUCinf ratio
    30 mg solid oral form of 0.78 0.88 0.92
    Example 1/30 mg oral
    solution (for comparison)

    These data indicate that the tested oral form shows bioavailability close to that observed for the IV form administered orally; a slight difference is observed for Tmax but the release obtained is very rapid and this is not detrimental to the desired therapeutic effect.
    • Example 10 Comparative Study Versus Reference Oral Solution
  • The data from the preceding study were compared with data given in the bibliography. Based on the linearity of the administered dose, the following values are obtained:
  • TABLE 6
    Pharmacokinetic parameters (arithmetic means -
    dose normalized to 30 mg)
    Cmax AUCt AUCinf
    Formulation (ng/mL) (ng/mL * h) (ng/mL * h)
    30 mg solid oral form 7.91 30.93 38.08
    of Example 1
    30 mg oral solution of nalbuphine 6.88 30.93 34.25
  • TABLE 7
    Relative bioavailability (based on arithmetic mean value -
    dose normalized to 30 mg)
    Formulation Cmax ratio AUCt ratio AUCinf ratio
    30 mg solid oral form of 1.15 1.00 1.11
    Example 1/30 mg oral
    solution (for comparison)
  • TABLE 8
    Pharmacokinetic parameters (geometric mean values -
    dose normalized to 30 mg)
    Cmax AUCinf
    Formulation (ng/mL) AUCt (ng/mL * h) (ng/mL * h)
    30 mg Solid oral form of 6.72 26.22 31.80
    Example 1
    30 mg Oral solution of 6.24 28.15 31.57
    nalbuphine
  • TABLE 9
    Relative bioavailability (based on geometric mean value
    normalized to a dose of 30 mg)
    30 mg solid oral form of Example 1/ 1.08 0.93 1.01
    30 mg oral solution (for comparison)

    On reasoning with geometric mean values, the bioavailability stated for the oral solution of nalbuphine is comparable with that observed for the solid form.
    • Example 11 Comparative Study Versus Oral Reference Solution
  • A second phase I study, with a single arm, was conducted on the oral formulation of Example 2 (30 mg tablets).
  • This study was completed by administering a single dose of 30 mg of nalbuphine to 12 male healthy volunteers with empty stomachs. Different parameters were measured: Tmax (time after which the maximum quantity of formulation is dissolved), Cmax (maximum quantity of dissolved formulation) and AUC (area located under the concentration versus time curve).
  • The observed data were compared with the data obtained during the study of example 9 for the intravenous form (IV) of nalbuphine administered orally,
  • Cmax Tmax AUCinf
    Formulation (ng/mL) (ng/mL) (ng/mL * h)
    30 mg oral solid form 12.2 2.63 38.1
    of Example 2
    30 mg oral liquid form (as a 9.3 3.11 39.1
    comparison)
  • Here also, the observed values are similar. It is noted that the values of Cmax and of AUC are close to each other. Tmax is shorter for the formulation according to example 2.

Claims (18)

1. Immediate release, oral pharmaceutical formulation comprising nalbuphine or a pharmaceutically acceptable salt thereof, and at least one hydrophilic granulation carrier, one hydrophilic binder and one lubricant.
2. The pharmaceutical formulation according to claim 1, wherein it only contains nalbuphine or one of the pharmaceutically acceptable salts thereof.
3. The pharmaceutical formulation according to claim 1, wherein the hydrophilic granulation carrier is selected from the group consisting of mannitol, polyvinyl pyrrolidone or a derivative thereof, a polyol, lactose, a cellulose derivative, polyethylene glycol or a derivative thereof and a silica derivative.
4. The pharmaceutical formulation according to claim 1, wherein the hydrophilic granulation carrier is lactose.
5. The pharmaceutical formulation according to claim 1, wherein the hydrophilic binder is selected from the group consisting of polyvinyl pyrrolidone or a derivative thereof, a polyol, lactose, a cellulose derivative, polyethylene glycol or a derivative thereof, gums and carbomers.
6. The pharmaceutical formulation according to claim 1, wherein the hydrophilic binder is polyvinylpyrrolidone.
7. The pharmaceutical formulation according to claim 1, wherein the lubricant is selected from the group consisting of silicon dioxide, magnesium stearate, anhydrous colloidal silica, sodium stearyl fumarate and talcum.
8. The pharmaceutical formulation according to claim 1, wherein it comprises at least 45% by weight of hydrophilic granulation carrier, relative to the total weight of the formulation.
9. The pharmaceutical formulation according to claim 1, wherein it comprises less than 10% by weight of hydrophilic binder, relative to the total weight of the formulation.
10. The pharmaceutical formulation according to claim 1, wherein it comprises less than 10% by weight of lubricant, relative to the total weight of the formulation.
11. The pharmaceutical formulation according to claim 1, wherein it comprises less than 30% by weight of nalbuphine, relative to the total weight of the formulation.
12. The pharmaceutical formulation according to claim 1, wherein it further comprises:
at least one disintegrating agent; and optionally
at least one excipient.
13. The pharmaceutical formulation according to claim 1, wherein it comprises:
from 4 to 30% by weight of nalbuphine;
from 45 to 70% by weight of lactose;
from 2 to 10% by weight of PVP; and
from 0.9 to 7% by weight of at least one lubricant.
14. The pharmaceutical formulation according to claim 1, wherein it is in solid form.
15. The pharmaceutical formulation according to claim 14, wherein it is in a form selected from the group consisting of tablets, granules, pellets, micro-granules, capsules and lozenges.
16. The pharmaceutical formulation according to claim 1, for its use in the treatment of pain.
17. The pharmaceutical formulation for use according to claim 16, wherein pain is generated by a treatment for opioid addiction.
18. The pharmaceutical formulation for use according to claim 1, its use in the treatment of opioid addiction.
US13/810,358 2010-08-20 2011-08-18 Formulations containing nalbuphine and uses thereof Abandoned US20130123294A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1056689 2010-08-20
FR1056689A FR2963889B1 (en) 2010-08-20 2010-08-20 NALBUPHINE-BASED FORMULATIONS AND USES THEREOF
PCT/FR2011/051929 WO2012022919A2 (en) 2010-08-20 2011-08-18 Nalbuphine-based formulations and uses thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2011/051929 A-371-Of-International WO2012022919A2 (en) 2010-08-20 2011-08-18 Nalbuphine-based formulations and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US15/170,033 Continuation US10441585B2 (en) 2010-08-20 2016-06-01 Formulations containing nalbuphine and uses thereof

Publications (1)

Publication Number Publication Date
US20130123294A1 true US20130123294A1 (en) 2013-05-16

Family

ID=43426302

Family Applications (2)

Application Number Title Priority Date Filing Date
US13/810,358 Abandoned US20130123294A1 (en) 2010-08-20 2011-08-18 Formulations containing nalbuphine and uses thereof
US15/170,033 Expired - Fee Related US10441585B2 (en) 2010-08-20 2016-06-01 Formulations containing nalbuphine and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
US15/170,033 Expired - Fee Related US10441585B2 (en) 2010-08-20 2016-06-01 Formulations containing nalbuphine and uses thereof

Country Status (31)

Country Link
US (2) US20130123294A1 (en)
EP (1) EP2605757B1 (en)
JP (2) JP2013534242A (en)
KR (1) KR101801424B1 (en)
CN (1) CN103025317B (en)
AR (1) AR082493A1 (en)
AU (1) AU2011290614B2 (en)
BR (1) BR112013004016A2 (en)
CA (1) CA2804333C (en)
CL (1) CL2013000477A1 (en)
CY (1) CY1116729T1 (en)
DK (1) DK2605757T3 (en)
EA (1) EA024945B1 (en)
ES (1) ES2548535T3 (en)
FR (1) FR2963889B1 (en)
HR (1) HRP20151021T1 (en)
HU (1) HUE027664T2 (en)
IL (1) IL224230A (en)
MA (1) MA34484B1 (en)
MX (1) MX354416B (en)
NZ (1) NZ605469A (en)
PH (1) PH12013500289A1 (en)
PL (1) PL2605757T3 (en)
PT (1) PT2605757E (en)
RS (1) RS54244B1 (en)
SG (1) SG187566A1 (en)
SI (1) SI2605757T1 (en)
SM (1) SMT201500257B (en)
TW (1) TWI522100B (en)
UA (1) UA110945C2 (en)
WO (1) WO2012022919A2 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9707184B2 (en) 2014-07-17 2017-07-18 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10195153B2 (en) 2013-08-12 2019-02-05 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US10959958B2 (en) 2014-10-20 2021-03-30 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10835495B2 (en) 2012-11-14 2020-11-17 W. R. Grace & Co.-Conn. Compositions containing a biologically active material and a non-ordered inorganic oxide material and methods of making and using the same
US8987289B2 (en) 2012-12-14 2015-03-24 Trevi Therapeutics, Inc. Methods for treating pruritus
AU2013359017B2 (en) * 2012-12-14 2018-05-10 Trevi Therapeutics, Inc. Methods for treating pruritus
US20140179727A1 (en) 2012-12-14 2014-06-26 Trevi Therapeutics, Inc. Methods for treating pruritus
US8637538B1 (en) 2012-12-14 2014-01-28 Trevi Therapeutics, Inc. Methods for treatment of pruritis
CN105560202B (en) * 2016-03-11 2019-05-24 广州玻思韬控释药业有限公司 A kind of preparation method and application of nalbuphlne hydrochloride gel skeleton sustained release tablets
IL318587A (en) 2018-07-23 2025-03-01 Trevi Therapeutics Inc Treatment of chronic cough, breathlessness and dyspnea
CN112739366B (en) 2018-09-14 2024-08-30 卡拉治疗学股份有限公司 Oral formulations of kappa opioid receptor agonists
CA3166928A1 (en) 2020-01-10 2021-07-15 Trevi Therapeutics, Inc. Methods of administering nalbuphine
KR20230002361A (en) 2020-03-18 2023-01-05 케러 테라퓨틱스, 인코포레이티드 Oligosaccharide Formulations of Kappa Opioid Receptor Agonists

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4366159A (en) * 1981-09-08 1982-12-28 Michael Richard Magruder Nalbuphine-narcotic analgesic composition and method of producing analgesia
US20090060871A1 (en) * 2006-04-25 2009-03-05 Michael Victor Voronkov Administration of agonist-antagonist in opioid-dependent patients

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4282215A (en) * 1980-06-17 1981-08-04 E. I. Du Pont De Nemours And Company Analgesic mixture of nalbuphine and acetylsalicylic acid, derivative or salt thereof
US4464378A (en) 1981-04-28 1984-08-07 University Of Kentucky Research Foundation Method of administering narcotic antagonists and analgesics and novel dosage forms containing same
US4477457A (en) * 1982-10-28 1984-10-16 E. I. Du Pont De Nemours And Company Method for inducing anorexia using nalmetrene
US6210714B1 (en) * 1993-11-23 2001-04-03 Euro-Celtique S.A. Immediate release tablet cores of acetaminophen having sustained-release coating
FI972718A0 (en) 1996-07-02 1997-06-24 More Magic Software Mms Oy Foerfaranden och arrangemang Foer distribution av ett anvaendargraenssnitt
US6372254B1 (en) * 1998-04-02 2002-04-16 Impax Pharmaceuticals Inc. Press coated, pulsatile drug delivery system suitable for oral administration
CA2343100A1 (en) 1998-09-08 2000-05-04 Srinivasan Venkateshwaran Method of making pressure sensitive adhesive matrix patches containing hydrophilic salts of drugs
JP2001089373A (en) * 1999-09-24 2001-04-03 Tanabe Seiyaku Co Ltd Oral formulation
CN1679556A (en) * 1999-12-08 2005-10-12 法马西亚公司 Valdecoxib compositions
KR20010107754A (en) * 2000-05-26 2001-12-07 민경윤 Process for preparing rapidly disintegrating tablet for oral administration
US7323192B2 (en) * 2001-09-28 2008-01-29 Mcneil-Ppc, Inc. Immediate release tablet
US6680067B2 (en) 2001-11-26 2004-01-20 Oliver Yoa-Pu Hu Controlled-release pharmaceutical preparation containing nalbuphine and a process for preparing the same
RU2254852C1 (en) 2004-01-23 2005-06-27 Ефим Давыдович Нежинский Injection solution with expressed analgesic effect and method for its preparing
US8394812B2 (en) * 2005-08-24 2013-03-12 Penwest Pharmaceuticals Co. Sustained release formulations of nalbuphine
ES2862573T3 (en) * 2005-08-24 2021-10-07 Endo Pharmaceuticals Inc Sustained Release Nalbuphine Formulations
AU2007335192A1 (en) * 2006-12-21 2008-06-26 Alphapharm Pty Ltd Pharmaceutical composition
US20080207667A1 (en) * 2007-02-23 2008-08-28 Rhame Robert W Use of nalbuphine and related compounds to treat symptoms of respiratory problems
WO2010085641A1 (en) * 2009-01-22 2010-07-29 Noramco, Inc. Process for preparing particles of opioids and compositions produced thereby
US8901113B2 (en) * 2009-09-30 2014-12-02 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4366159A (en) * 1981-09-08 1982-12-28 Michael Richard Magruder Nalbuphine-narcotic analgesic composition and method of producing analgesia
US20090060871A1 (en) * 2006-04-25 2009-03-05 Michael Victor Voronkov Administration of agonist-antagonist in opioid-dependent patients

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
"Pharmainfo" Tablet Disintegrants (http://www.pharmainfo.net/tablet-disintegrants) accessed 19 January 2016. *
"Tablettose" (http://www.meggle-pharma.com/index.php/en/products-and-services/products/product-overview/tablettose-80-agglomerated-) available 7 February 2011. *
Aungst et al. "ORAL AND RECTAL NALBUPHINE BIOAVAILABILITY: FIRST-PASS METABOLISM IN RATS AND DOGS" Biopharm & Drug Disposition, 1985, 6, 413-321 *
Buhler, V. "Polyvinylpyrrolidone Excipients for Pharmaceuticals: Povidone, Crospovidone and Copovidone" 2005, pgs 1-254. *
Rubinstein, M.H.; Rughani, J.M. "THE EFFECT OF FOUR TABLET BINDERS ON THE BIOAVAILABILITY OF FRUSEMIDE FROM 40MG TABLETS" Drug Dev. Ind. Pharm. 1978, 4 (6), 541-553 *
Rudnic, E.M.; Schwartz, J.B. Remington: The Science and Practice of Pharmacy, 21st Edition. 2005, Ch 45, pgs 889-928 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10195153B2 (en) 2013-08-12 2019-02-05 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US10639281B2 (en) 2013-08-12 2020-05-05 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10792254B2 (en) 2013-12-17 2020-10-06 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9707184B2 (en) 2014-07-17 2017-07-18 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
US10959958B2 (en) 2014-10-20 2021-03-30 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form

Also Published As

Publication number Publication date
MX2013001985A (en) 2013-05-09
TW201302198A (en) 2013-01-16
WO2012022919A2 (en) 2012-02-23
SI2605757T1 (en) 2015-11-30
JP2016166230A (en) 2016-09-15
PH12013500289A1 (en) 2016-10-26
TWI522100B (en) 2016-02-21
MA34484B1 (en) 2013-08-01
US20160271124A1 (en) 2016-09-22
CL2013000477A1 (en) 2013-06-28
EA024945B1 (en) 2016-11-30
CY1116729T1 (en) 2017-03-15
AU2011290614A1 (en) 2013-01-31
KR20130099914A (en) 2013-09-06
FR2963889B1 (en) 2013-04-12
ES2548535T3 (en) 2015-10-19
BR112013004016A2 (en) 2016-06-28
HUE027664T2 (en) 2016-10-28
EP2605757B1 (en) 2015-07-01
MX354416B (en) 2018-03-05
AR082493A1 (en) 2012-12-12
JP2013534242A (en) 2013-09-02
FR2963889A1 (en) 2012-02-24
US10441585B2 (en) 2019-10-15
AU2011290614B2 (en) 2015-11-19
IL224230A (en) 2017-03-30
HRP20151021T1 (en) 2015-11-06
EA201300258A1 (en) 2013-06-28
WO2012022919A3 (en) 2012-05-10
SMT201500257B (en) 2016-01-08
CA2804333A1 (en) 2012-02-23
PT2605757E (en) 2015-10-19
DK2605757T3 (en) 2015-10-05
KR101801424B1 (en) 2017-11-24
SG187566A1 (en) 2013-03-28
PL2605757T3 (en) 2015-12-31
RS54244B1 (en) 2015-12-31
CA2804333C (en) 2019-03-19
NZ605469A (en) 2015-01-30
EP2605757A2 (en) 2013-06-26
JP6173521B2 (en) 2017-08-02
CN103025317B (en) 2016-08-17
UA110945C2 (en) 2016-03-10
CN103025317A (en) 2013-04-03

Similar Documents

Publication Publication Date Title
US10441585B2 (en) Formulations containing nalbuphine and uses thereof
JP4740740B2 (en) Drug-containing particles and solid preparation containing the particles
JPWO2002024166A1 (en) Oral formulation with good disintegration
US20240041782A1 (en) Oral Capsule Cannabinoid Formulations
US20110189274A1 (en) Stable Pharmaceutical Compositions Of Montelukast Or Its Salts Or Solvates Or Hydrates
EP3733167A1 (en) Novel fine particle coating (drug-containing hollow particle and method for manufacturing same)
US20140343076A1 (en) Pharmaceutical compositions of lurasidone
AU2011379627B2 (en) Sublingual pharmaceutical composition containing an antihistamine agent and method for the preparation thereof
WO2018124282A1 (en) Pharmaceutical composition and method for producing same
US20210220373A1 (en) Orally disintegrating pharmacutical composition comprising nefopam and process for preparing the same
EP3796908B1 (en) Controlled release propiverine formulations
CN112315927A (en) Paliperidone sustained-release orally disintegrating tablet and preparation method thereof
JP4754485B2 (en) Coprecipitation active substance-containing particles
US11819482B2 (en) Composition comprising suplatast tosilate
JP2008081448A (en) Zolpidem tartrate bitterness masking immediate release particles
WO2005016315A1 (en) Pharmaceutical compositions of nateglinide and a high amount of a water-soluble filler
US20210346303A1 (en) Coating method

Legal Events

Date Code Title Description
AS Assignment

Owner name: DEBREGEAS ET ASSOCIES PHARMA, FRANCE

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LEBON, CHRISTOPHE;SUPLIE, PASCAL;PAUL, DAVID OLIVIER;REEL/FRAME:029645/0452

Effective date: 20130107

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION